Celecoxib
- Generic Name
- Celecoxib
- Brand Names
- Celebrex, Elyxyb, Seglentis
- Drug Type
- Small Molecule
- Chemical Formula
- C17H14F3N3O2S
- CAS Number
- 169590-42-5
- Unique Ingredient Identifier
- JCX84Q7J1L
- Background
Celecoxib, a selective cyclooxygenase-2 (COX-2) inhibitor, is a nonsteroidal anti-inflammatory drug (NSAID) which is known for its decreased risk of causing gastrointestinal bleeding compared to other NSAIDS. It is used to manage symptoms of various types of arthritis pain and in familial adenomatous polyposis (FAP) to reduce precancerous polyps in the colon. It is marketed by Pfizer under the brand name Celebrex, and was initially granted FDA approval in 1998.
Interestingly, selective COX-2 inhibitors (especially celecoxib), have been evaluated as potential cancer chemopreventive and therapeutic drugs in clinical trials for a variety of malignancies.
- Indication
Celecoxib is indicated for symptomatic treatment of adult osteoarthritis (OA) and adult rheumatoid arthritis (RA). Celecoxib is not a substitute for aspirin for cardiovascular event prophylaxis.
It may be also be used to treat acute pain from various sources, juvenile rheumatoid arthritis in children over 2, ankylosing spondylitis, and primary dysmenorrhea.
Celecoxib, in combination with tramadol, is indicated for the management of acute pain in adults severe enough to require an opioid analgesic and in whom alternative treatments are inadequate.
- Associated Conditions
- Acute Pain, Ankylosing Spondylitis (AS), Osteoarthritis (OA), Primary Dysmenorrhoea, Rheumatoid Arthritis, Rheumatoid Arthritis, Juvenile, Severe Acute Pain
Clinical Study Evaluating Safety of Pentoxifylline and Celecoxib in Patients With Grand-Mal Epilepsy Treated by Phenytoin Monotherapy
- Conditions
- Epilepsy
- Interventions
- First Posted Date
- 2022-12-05
- Last Posted Date
- 2024-07-18
- Lead Sponsor
- Mostafa Bahaa
- Target Recruit Count
- 90
- Registration Number
- NCT05637086
- Locations
- 🇪🇬
Mansoura University, Mansoura, Egypt
Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, Food Effect and DDI of Ascending Doses of the MEK Inhibitor Zapnometinib
- Conditions
- Healthy
- Interventions
- First Posted Date
- 2022-09-27
- Last Posted Date
- 2023-08-01
- Lead Sponsor
- Atriva Therapeutics GmbH
- Target Recruit Count
- 96
- Registration Number
- NCT05555823
- Locations
- 🇩🇪
Atriva study site, Neu-Ulm, Germany
Multimodal and Unimodal Analgesia in Cholecystectomy
- Conditions
- Compare Unimodal and Multimodal Analgesics
- Interventions
- First Posted Date
- 2022-09-21
- Last Posted Date
- 2022-09-21
- Lead Sponsor
- October 6 University
- Target Recruit Count
- 95
- Registration Number
- NCT05547659
- Locations
- 🇪🇬
Beni suef University hospital, Banī Suwayf, Egypt
🇪🇬Beni-Suef Hospital, Banī Suwayf, Egypt
The Effects of NSAIDs on Bone Metabolism Following Exercise
- Conditions
- Bone ResorptionStress FractureBone Injury
- Interventions
- First Posted Date
- 2022-08-23
- Last Posted Date
- 2023-11-29
- Lead Sponsor
- United States Army Research Institute of Environmental Medicine
- Target Recruit Count
- 12
- Registration Number
- NCT05512013
- Locations
- 🇺🇸
United States Army Research Institute of Environmental Medicine, Natick, Massachusetts, United States
Opioid-Free Pain Protocol After Shoulder Arthroplasty
- Conditions
- Shoulder ArthropathyShoulder Pain
- Interventions
- First Posted Date
- 2022-08-05
- Last Posted Date
- 2025-02-17
- Lead Sponsor
- Henry Ford Health System
- Target Recruit Count
- 80
- Registration Number
- NCT05488847
- Locations
- 🇺🇸
Henry Ford Health, Detroit, Michigan, United States
A Multiple-Dose PK Study to Evaluate the Comparative Bioavailability of PrimeC Tablets to Ciprofloxacin Tablets Co-administered With Celecoxib Capsules, in Healthy Adult Subject
- Conditions
- Pharmacokinetics
- Interventions
- First Posted Date
- 2022-06-29
- Last Posted Date
- 2023-02-08
- Lead Sponsor
- NeuroSense Therapeutics Ltd.
- Target Recruit Count
- 19
- Registration Number
- NCT05436678
- Locations
- 🇺🇸
Novum, Las Vegas, Nevada, United States
Study to Assess the Effect of Co-Administration of AZD9833 on the Pharmacokinetics of Midazolam, of Omeprazole, of Celecoxib and of Dabigatran Etexilate in Healthy Postmenopausal Female Volunteers
- Conditions
- Healthy Volunteers
- Interventions
- First Posted Date
- 2022-06-29
- Last Posted Date
- 2023-01-12
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 59
- Registration Number
- NCT05438303
- Locations
- 🇺🇸
Research Site, Berlin, New Jersey, United States
Effects and Mechanisms of Celecoxib on Intracerebral Hemorrhage
- First Posted Date
- 2022-06-27
- Last Posted Date
- 2023-07-18
- Lead Sponsor
- National Taiwan University Hospital
- Target Recruit Count
- 60
- Registration Number
- NCT05434065
- Locations
- 🇨🇳
Natinal Taiwan University Hospital, Taipei, Taiwan
Treating Immuno-metabolic Depression With Anti-inflammatory Drugs
- Conditions
- Depressive Disorder, MajorInflammation
- Interventions
- Drug: Placebo
- First Posted Date
- 2022-06-13
- Last Posted Date
- 2024-11-18
- Lead Sponsor
- Amsterdam UMC, location VUmc
- Target Recruit Count
- 140
- Registration Number
- NCT05415397
- Locations
- 🇳🇱
Department of Psychiatry Amsterdam UMC, Amsterdam, Netherlands
Possible Protective Effect of Celecoxib Against Capecitabine Induced Hand and Foot Syndrome in Patients With Colorectal Cancer
- Conditions
- Hand and Foot SyndromeErythrodysesthesia SyndromeHFSColorectal Cancer
- Interventions
- Drug: Capecitabine-based chemotherapy
- First Posted Date
- 2022-04-14
- Last Posted Date
- 2022-04-14
- Lead Sponsor
- Tanta University
- Target Recruit Count
- 44
- Registration Number
- NCT05327751
- Locations
- 🇪🇬
Faculty of Pharmacy-Tanta University, Tanta, Egypt
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.